US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in Japan- ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary ... and management of retinal vein occlusion.

Whether it’s something as common as cataracts or more complex conditions like progressive retinal atrophy (PRA), understanding these health risks is key. In this article, we’ll explore the breeds most ...

placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA). The topline data showed that ATH434 produced clinically and statistically significant improvement ...

placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA). The topline data showed that ATH434 produced clinically and statistically significant ...